Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 19

1.

A randomized controlled trial utilizing motivational interviewing to reduce HIV risk and drug use in young gay and bisexual men.

Parsons JT, Lelutiu-Weinberger C, Botsko M, Golub SA.

J Consult Clin Psychol. 2014 Feb;82(1):9-18. doi: 10.1037/a0035311. Epub 2013 Dec 23.

2.

Aggregate versus day level association between methamphetamine use and HIV medication non-adherence among gay and bisexual men.

Parsons JT, Kowalczyk WJ, Botsko M, Tomassilli J, Golub SA.

AIDS Behav. 2013 May;17(4):1478-87. doi: 10.1007/s10461-013-0463-7.

3.

Predictors of day-level sexual risk for young gay and bisexual men.

Parsons JT, Lelutiu-Weinberger C, Botsko M, Golub SA.

AIDS Behav. 2013 May;17(4):1465-77. doi: 10.1007/s10461-012-0206-1.

4.

Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings.

Lum PJ, Little S, Botsko M, Hersh D, Thawley RE, Egan JE, Mitty J, Boverman J, Fiellin DA; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S91-7. doi: 10.1097/QAI.0b013e31820a9a82.

PMID:
21317601
5.

Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.

Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, Sohler N, Tozzi MJ, Asch SM, Botsko M, Fishl M, Flanigan TP, Boverman J, McCarty D; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S83-90. doi: 10.1097/QAI.0b013e31820bc9a5.

6.

The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation.

Schackman BR, Leff JA, Botsko M, Fiellin DA, Altice FL, Korthuis PT, Sohler N, Weiss L, Egan JE, Netherland J, Gass J, Finkelstein R; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S76-82. doi: 10.1097/QAI.0b013e31820a9a66.

7.

Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients.

Vergara-Rodriguez P, Tozzi MJ, Botsko M, Nandi V, Altice F, Egan JE, O'Connor PG, Sullivan LE, Fiellin DA; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S62-7. doi: 10.1097/QAI.0b013e31820a820f.

PMID:
21317596
8.

The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone.

Sullivan LE, Botsko M, Cunningham CO, O'Connor PG, Hersh D, Mitty J, Lum PJ, Schottenfeld RS, Fiellin DA; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S54-61. doi: 10.1097/QAI.0b013e3182097576.

9.

Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics.

Korthuis PT, Tozzi MJ, Nandi V, Fiellin DA, Weiss L, Egan JE, Botsko M, Acosta A, Gourevitch MN, Hersh D, Hsu J, Boverman J, Altice FL; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S39-45. doi: 10.1097/QAI.0b013e318209754c.

10.

Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.

Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, Chaudhry A, Cunningham CO, Gourevitch MN, Lum PJ, Sullivan LE, Schottenfeld RS, O'Connor PG; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S33-8. doi: 10.1097/QAI.0b013e3182097537.

11.

HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.

Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S22-32. doi: 10.1097/QAI.0b013e318209751e.

12.

Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.

Chaudhry AA, Botsko M, Weiss L, Egan JE, Mitty J, Estrada B, Lucas GM, Woodson T, Flanigan TP, Fiellin DA; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S14-21. doi: 10.1097/QAI.0b013e318209d3b9.

PMID:
21317589
13.

The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment.

Weiss L, Egan JE, Botsko M, Netherland J, Fiellin DA, Finkelstein R.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S7-13. doi: 10.1097/QAI.0b013e3182097426.

PMID:
21317598
14.

More than ancillary: HIV social services, intermediate outcomes and quality of life.

Chin JJ, Botsko M, Behar E, Finkelstein R.

AIDS Care. 2009 Oct;21(10):1289-97. doi: 10.1080/09540120902732019.

PMID:
20024705
15.

Factors affecting willingness to provide buprenorphine treatment.

Netherland J, Botsko M, Egan JE, Saxon AJ, Cunningham CO, Finkelstein R, Gourevitch MN, Renner JA, Sohler N, Sullivan LE, Weiss L, Fiellin DA; BHIVES Collaborative.

J Subst Abuse Treat. 2009 Apr;36(3):244-51. doi: 10.1016/j.jsat.2008.06.006. Epub 2008 Aug 20.

16.

The CASE adherence index: A novel method for measuring adherence to antiretroviral therapy.

Mannheimer SB, Mukherjee R, Hirschhorn LR, Dougherty J, Celano SA, Ciccarone D, Graham KK, Mantell JE, Mundy LM, Eldred L, Botsko M, Finkelstein R.

AIDS Care. 2006 Oct;18(7):853-61.

17.

A preventive services program model for preserving and supporting families over time.

Hess PM, McGowan BG, Botsko M.

Child Welfare. 2000 May-Jun;79(3):227-65.

PMID:
10813083
18.

Workplace smoking policies in New Jersey businesses.

Lewit EM, Botsko M, Shapiro S.

Am J Public Health. 1993 Feb;83(2):254-6.

19.

The response of restaurants to New Jersey's smoking control law.

Lewit EM, Botsko M, Meinert L.

N J Med. 1992 Jul;89(7):531-5.

PMID:
1305271
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk